Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2052.1995.tb02653.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of the Mobile Active Site Flap in IMP Dehydrogenase Inhibitor Binding.
ACS Infect Dis
January 2025
Department of Chemistry, Brandeis University, Waltham, Massachusetts 02454, United States.
Inosine 5'-monophosphate dehydrogenase (IMPDH) is a promising antibiotic target. This enzyme catalyzes the NAD-dependent oxidation of inosine 5'-monophosphate (IMP) to xanthosine 5'-monophosphate (XMP), which is the rate-limiting step in guanine nucleotide biosynthesis. Bacterial IMPDH-specific inhibitors have been developed that bind to the NAD site.
View Article and Find Full Text PDFExposure to major coronary heart disease events reduces lung cancer risk: a mendelian randomization study based on a European population.
BMC Cancer
January 2025
Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, 530021, P. R. China.
Objective: This study seeks to elucidate the causal relationship between major coronary heart disease events (MCHDE) and lung cancer incidence through mendelian randomization (MR), with the goal of providing evidence to inform more effective lung cancer screening and prevention strategies.
Methods: Utilizing data from the IEU OpenGWAS project and FinnGen, this study employed a two-sample MR approach, with genetic variants serving as instrumental variables. Relevant single nucleotide polymorphisms (SNPs) associated with MCHDE and lung cancer were carefully selected, with particular attention given to mitigating potential confounders, such as smoking behaviors and statin use.
Background: Deficiency of 17β-hydroxysteroid dehydrogenase type 3 (HSD17B3) is a rare variant of 46,XY disorders of sex development (DSD).
Aim: To give clinical, hormonal and molecular genetic characteristics of cases of 46,XY DSD associated with variants in the HSD17B3 gene.
Materials And Methods: The study included 310 patients with 46,XY DSD for the period from 2015 to 2019.
Identification of the Novel HLA-C*06:44:02 Allele by Next-Generation Sequencing in a Serbian Individual.
HLA
January 2025
School of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina.
The novel HLA-C*06:44:02 allele differs from HLA-C*06:44:01 by one synonymous nucleotide substitution in exon 2.
View Article and Find Full Text PDFThe New HLA-B*44:384 Allele Characterised by Two Different Sequencing-Based Typing Techniques.
HLA
January 2025
HLA and Histocompatibility Laboratory, CHRU de Nancy, Vandœuvre-lès-Nancy, France.
The new allele HLA-B*44:384 differs from HLA-B*44:02:01:01 by one non-synonymous nucleotide substitution in exon 2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!